U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H19N3O3S
Molecular Weight 357.4285
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROSIGLITAZONE

SMILES

CN(CCOc1ccc(cc1)CC2C(=NC(=O)S2)O)c3ccccn3

InChI

InChIKey=YASAKCUCGLMORW-UHFFFAOYSA-N
InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)

HIDE SMILES / InChI

Molecular Formula C18H19N3O3S
Molecular Weight 357.4285
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/mtm/rosiglitazone.html http://www.rxlist.com/avandia-drug.htm http://www.wikidoc.org/index.php/Rosiglitazone

Rosiglitazone acts as a highly selective and potent agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. It is FDA approved for the treatment of as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Inhibitors of CYP2C8 (e.g., gemfibrozil) may increase rosiglitazone levels; inducers of CYP2C8 (e.g., rifampin) may decrease rosiglitazone levels. Common adverse reactions include edema, weight gain, and headache.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AVANDIA

Approved Use

After consultation with a healthcare professional who has considered and advised the patient of the risks and benefits of rosiglitazone, AVANDAMET® is indicated as an adjunct to diet and exercise to improve glycemic control when treatment with both rosiglitazone and metformin is appropriate in adults with type 2 diabetes mellitus who either are: already taking rosiglitazone, or not already taking rosiglitazone and unable to achieve glycemic control on other diabetes medications and, in consultation with their healthcare provider, have decided not to take pioglitazone (ACTOS®) or pioglitazone-containing products (ACTOPLUS MET®, ACTOPLUS MET XR®, DUETACT®) for medical reasons. Other Important Limitations of Use: Due to its mechanism of action, rosiglitazone is active only in the presence of endogenous insulin. Therefore, AVANDAMET should not be used in patients with type 1 diabetes. Coadministration of AVANDAMET with insulin is not recommended [see Warnings and Precautions (5.2, 5.3)

Launch Date

9.2759038E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
432 ng/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
598 ng/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2890 ng × h/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
2971 ng × h/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.59 h
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
3.37 h
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.105
unhealthy, 53.1
n = 32
Health Status: unhealthy
Condition: Nonalcoholic steatohepatitis
Age Group: 53.1
Sex: M+F
Population Size: 32
Sources: Page: p.105
DLT: Headache, Malaise...
Disc. AE: Pain in leg...
Dose limiting toxicities:
Headache (3.1%)
Malaise (3.1%)
Oedema legs (9.4%)
AEs leading to
discontinuation/dose reduction:
Pain in leg (3.1%)
Sources: Page: p.105
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources: Page: p.73,74
unhealthy, 60
n = 1
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Age Group: 60
Sex: M
Population Size: 1
Sources: Page: p.73,74
Disc. AE: Macular edema...
AEs leading to
discontinuation/dose reduction:
Macular edema
Sources: Page: p.73,74
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Disc. AE: Congestive heart failure, Myocardial ischemia...
AEs leading to
discontinuation/dose reduction:
Congestive heart failure
Myocardial ischemia (2%)
Fluid retention
Edema
Weight gain
Anemia
Macular edema
Fracture bone
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Headache 3.1%
DLT
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.105
unhealthy, 53.1
n = 32
Health Status: unhealthy
Condition: Nonalcoholic steatohepatitis
Age Group: 53.1
Sex: M+F
Population Size: 32
Sources: Page: p.105
Malaise 3.1%
DLT
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.105
unhealthy, 53.1
n = 32
Health Status: unhealthy
Condition: Nonalcoholic steatohepatitis
Age Group: 53.1
Sex: M+F
Population Size: 32
Sources: Page: p.105
Pain in leg 3.1%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.105
unhealthy, 53.1
n = 32
Health Status: unhealthy
Condition: Nonalcoholic steatohepatitis
Age Group: 53.1
Sex: M+F
Population Size: 32
Sources: Page: p.105
Oedema legs 9.4%
DLT
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.105
unhealthy, 53.1
n = 32
Health Status: unhealthy
Condition: Nonalcoholic steatohepatitis
Age Group: 53.1
Sex: M+F
Population Size: 32
Sources: Page: p.105
Macular edema Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources: Page: p.73,74
unhealthy, 60
n = 1
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Age Group: 60
Sex: M
Population Size: 1
Sources: Page: p.73,74
Myocardial ischemia 2%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Anemia Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Congestive heart failure Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Edema Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Fluid retention Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Fracture bone Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Macular edema Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Weight gain Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
PubMed

PubMed

TitleDatePubMed
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.
2002 Jul
AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.
2002 Nov
Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone.
2002 Nov
Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
2003 Apr
Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect.
2003 Aug 15
Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma.
2003 Dec
Rosiglitazone produces insulin sensitisation by increasing expression of the insulin receptor and its tyrosine kinase activity in brown adipocytes.
2003 Dec
Diminished production of nitric oxide synthase cofactor tetrahydrobiopterin by rosiglitazone in adipocytes.
2003 Feb 15
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs.
2003 Feb 7
Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al.
2003 Jan
Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.
2003 Jan 1
Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells.
2003 Jul 1
PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist.
2003 Oct
Induction of apoptosis by mono(2-ethylhexyl)phthalate (MEHP) in U937 cells.
2003 Oct 15
A phase II trial with rosiglitazone in liposarcoma patients.
2003 Oct 20
Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.
2003 Sep
Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes.
2003 Sep
Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.
2004 Apr
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
2004 Aug
The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
2004 Aug
[Anti-hypertensive effect of rosiglitazone in non-diabetic essential hypertension].
2004 Dec
Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers.
2004 Dec
Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.
2004 Dec 1
Bone is a target for the antidiabetic compound rosiglitazone.
2004 Jan
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation.
2004 Jan 1
Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin.
2004 Jul 1
Evidence for a potent antiinflammatory effect of rosiglitazone.
2004 Jun
PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice.
2004 Mar
Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy.
2004 Mar 23
Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone.
2004 Nov
Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone.
2004 Nov
Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism.
2004 Nov
Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro.
2004 Oct
Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation.
2004 Oct 22
Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.
2004 Sep
Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors.
2005
Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
2005 Aug
Rosiglitazone, PPAR-gamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro.
2005 Feb
Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines.
2005 Feb
Rosiglitazone up-regulates lipoprotein lipase, hormone-sensitive lipase and uncoupling protein-1, and down-regulates insulin-induced fatty acid synthase gene expression in brown adipocytes of Wistar rats.
2005 Jun
Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1.
2005 Jun
Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
2005 Mar
The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency.
2005 Mar
Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism.
2005 Mar
The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes.
2005 May
Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.
2005 May
Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma.
2005 May
Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway.
2005 May
Selective activation of PPARgamma in breast, colon, and lung cancer cell lines.
2005 May 12
Fatty acids and expression of adipokines.
2005 May 30
Patents

Sample Use Guides

Start at 4 mg daily in single or divided doses; do not exceed 8 mg daily.
Route of Administration: Oral
Rosiglitazone treatment (5 uM) prevents NO and prostacyclin overproduction by inhibiting microparticles-induced iNOS and COX-2 expression.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:50:48 UTC 2021
Edited
by admin
on Fri Jun 25 21:50:48 UTC 2021
Record UNII
05V02F2KDG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROSIGLITAZONE
EMA EPAR   HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
ROSIGLIZOLE
Brand Name English
BRL-49653
Code English
NSC-758698
Code English
ROSIGLITAZONE [WHO-DD]
Common Name English
ROSIGLITAZONE [MI]
Common Name English
ROSIGLITAZONE [INN]
Common Name English
ROSIGLITAZONE [EMA EPAR]
Common Name English
REZULT
Brand Name English
TDZ-01
Code English
ROSIGLITAZONE [VANDF]
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-(2-(METHYL-2-PYRIDINYLAMINO)ETHOXY)PHENYL)METHYL)-
Systematic Name English
ROSIGLITAZONE [MART.]
Common Name English
ROSIGLITAZONE [IARC]
Common Name English
ROSVEL
Brand Name English
GAUDIL
Brand Name English
5-((4-(2-(METHYL-2-PYRIDINYLAMINO)ETHOXY)PHENYL)METHYL)-2,4-THIAZOLIDINEDIONE
Systematic Name English
ROSIGLITAZONE [HSDB]
Common Name English
5-(4-(2-(N-METHYL-N-(2-PYRIDINYL)AMINO)ETHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C98241
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
NDF-RT N0000011272
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
WHO-ATC A10BD03
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
LIVERTOX 863
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
NDF-RT N0000180190
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
WHO-ATC A10BD04
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
WHO-VATC QA10BG02
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
NDF-RT N0000175374
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
NCI_THESAURUS C1934
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
WHO-VATC QA10BD04
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
WHO-ATC A10BG02
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
NDF-RT N0000170119
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
NDF-RT N0000011272
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
WHO-VATC QA10BD03
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
NDF-RT N0000180186
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
NDF-RT N0000170119
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
NDF-RT N0000011272
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
Code System Code Type Description
EVMPD
SUB10388MIG
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY
DRUG CENTRAL
2405
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY
INN
7662
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY
PUBCHEM
77999
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY
HSDB
7555
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY
DRUG BANK
DB00412
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY
LACTMED
Rosiglitazone
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY
WIKIPEDIA
ROSIGLITAZONE
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY
IUPHAR
1056
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY
MESH
C089730
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY
NCI_THESAURUS
C62076
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY
EPA CompTox
122320-73-4
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY
MERCK INDEX
M9666
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY Merck Index
CAS
122320-73-4
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY
ChEMBL
CHEMBL121
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY
FDA UNII
05V02F2KDG
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY
RXCUI
84108
Created by admin on Fri Jun 25 21:50:49 UTC 2021 , Edited by admin on Fri Jun 25 21:50:49 UTC 2021
PRIMARY RxNorm
Related Record Type Details
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
SUBSTRATE USED: Bromsulphthalein (BSP)
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE INACTIVE -> PARENT
MINOR
METABOLITE ACTIVE -> PARENT
MAJOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC